Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 6
2016 5
2017 2
2018 3
2019 2
2020 1
2021 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor.
You D, Hillerman S, Locke G, Chaudhry C, Stromko C, Murtaza A, Fan Y, Koenitzer J, Chen Y, Briceno S, Bhadra R, Duperret E, Gullo-Brown J, Gao C, Zhao D, Feder J, Curtin J, Degnan AP, Kumi G, Wittman M, Johnson BM, Parrish KE, Gokulrangan G, Morrison J, Quigley M, Hunt JT, Salter-Cid L, Lees E, Sanjuan MA, Liu J. You D, et al. Among authors: parrish ke. J Immunother Cancer. 2021 Jan;9(1):e001402. doi: 10.1136/jitc-2020-001402. J Immunother Cancer. 2021. PMID: 33408094 Free PMC article.
Long-Acting Tumor-Activated Prodrug of a TGFβR Inhibitor.
Zhang Y, Parrish KE, Tortolani DR, Poss MA, Huang A, Wan H, Purandare AV, Donnell AF, Kempson J, Hou X, Pawluczyk J, Yip S, Luk E, Raghavan N, Swanson J, Smalley J, Murtaza A, Yang Z, Augustine-Rauch K, Lombardo LJ, Borzilleri R. Zhang Y, et al. Among authors: parrish ke. J Med Chem. 2021 Nov 11;64(21):15787-15798. doi: 10.1021/acs.jmedchem.0c02043. Epub 2021 Oct 27. J Med Chem. 2021. PMID: 34704759
Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1.
Degnan AP, Kumi GK, Allard CW, Araujo EV, Johnson WL, Zimmermann K, Pearce BC, Sheriff S, Futran A, Li X, Locke GA, You D, Morrison J, Parrish KE, Stromko C, Murtaza A, Liu J, Johnson BM, Vite GD, Wittman MD. Degnan AP, et al. Among authors: parrish ke. ACS Med Chem Lett. 2021 Feb 19;12(3):443-450. doi: 10.1021/acsmedchemlett.0c00660. eCollection 2021 Mar 11. ACS Med Chem Lett. 2021. PMID: 33732413 Free PMC article.
Challenges in the delivery of therapies to melanoma brain metastases.
Gampa G, Vaidhyanathan S, Resman BW, Parrish KE, Markovic SN, Sarkaria JN, Elmquist WF. Gampa G, et al. Among authors: parrish ke. Curr Pharmacol Rep. 2016 Dec;2(6):309-325. doi: 10.1007/s40495-016-0072-z. Epub 2016 Nov 9. Curr Pharmacol Rep. 2016. PMID: 28546917 Free PMC article.
In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling.
Kizilbash SH, Gupta SK, Parrish KE, Laramy JK, Kim M, Gampa G, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Elmquist WF, Sarkaria JN. Kizilbash SH, et al. Among authors: parrish ke. Mol Cancer Ther. 2021 Jun;20(6):1009-1018. doi: 10.1158/1535-7163.MCT-20-0640. Epub 2021 Mar 30. Mol Cancer Ther. 2021. PMID: 33785646 Free PMC article.
22 results